Mayne Pharma Group Limited (ASX: MYX), a specialty pharmaceutical company, has commercially launched a generic version of ORTHO-CEPT (desogestrel and ethinyl estradiol 0.15mg/0.03mg) tablets in the United States, it was reported on Thursday.

The product is the fourth oral contraceptive introduced in 2021 after launching generic versions of LOESTRIN 24 FE, ORTHO CYCLEN and ORTHO TRI-CYCLEN.

Mayne Pharma's CEO, Scott Richards, said, 'We are very pleased to expand our Women's Health portfolio, which now covers ~80 percent of Obstetrician/Gynaecologist oral contraceptive prescription volumes [1] and includes 24 marketed branded generic contraceptives. Mayne Pharma is committed to helping meet the needs of women in the US by providing cost effective, high-quality and novel contraceptive options. The four new products launched this year were sourced from the strategic partnership with Novast Laboratories.'

[1] IQVIA, MAT Sales and NSP Units for brand and generic equivalents, January 2021